SCHEMBL3960601

SCHEMBL3960601

Cc1ccc(O)c(CC(C)C)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 2/20 0.66
GABRB2 P47870 2/20 0.66
AMY1A P0DUB6 1/20 0.55
TRPA1 O75762 2/20 0.48
TP53 P04637 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
LMNA P02545 3/20 0.45
CHRM1 P11229 1/20 0.45
SLC6A2 P23975 1/20 0.45
ADRA1A P35348 1/20 0.45
HTR2B P41595 1/20 0.45
HTT P42858 1/20 0.45
HSD17B10 Q99714 3/20 0.44
HPGD P15428 3/20 0.44
KDM4E B2RXH2 1/20 0.44
USP2 O75604 1/20 0.44
ALOX15 P16050 3/20 0.43
ALDH1A1 P00352 1/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15667381 0.86 AMY1A (0.53) GABRA1GABRB2AMY1ATRPA1TP53
SCHEMBL15666912 0.86 AMY1A (0.53) GABRA1GABRB2AMY1ATRPA1TP53
SCHEMBL15666913 0.86 AMY1A (0.53) GABRA1GABRB2AMY1ATRPA1TP53
SCHEMBL14478234 0.84 AMY1A (0.52) GABRA1GABRB2AMY1ATRPA1TP53
SCHEMBL3953639 0.83 TRPA1 (0.50) GABRA1GABRB2AMY1ATRPA1TP53
SCHEMBL23153076 0.82 AMY1A (0.50) GABRA1GABRB2AMY1ATRPA1TP53
SCHEMBL806464 0.82 AMY1A (0.50) GABRA1GABRB2AMY1ATRPA1TP53
SCHEMBL5877825 0.81 GABRA1 (0.68) GABRA1GABRB2TRPA1TP53TDP1
SCHEMBL1581538 0.80 GABRA1 (0.61) GABRA1GABRB2TRPA1TP53TDP1
SCHEMBL6278017 0.79 AMY1A (0.70) GABRA1GABRB2AMY1ATRPA1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115243764-B Heterocyclic derivatives as TRMP antagonists 奇华顿股份有限公司 2025-01-03 CN disclosed
US-20230098332-A1 HETEROCYCLIC DERIVATIVES AS TRMP8 ANTAGONISTS GIVAUDAN SA (CH) 2023-03-30 US disclosed
EP-4114523-A1 HETEROCYCLIC DERIVATIVES AS TRMP8 ANTAGONISTS Givaudan SA (CH) 2023-01-11 EP disclosed
CN-115243764-A Heterocyclic derivatives as TRMP8 antagonists 奇华顿股份有限公司 2022-10-25 CN disclosed
US-10960088-B2 Macrocycles, cobalt and iron complexes of same, and methods of making and using same THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2021-03-30 US disclosed
US-10422047-B2 Electrochemical process for coupling of phenol to aniline EVONIK DEGUSSA GMBH (DE) 2019-09-24 US disclosed
US-20180030244-A1 Alternative Methods to Control Crosslinking in High Impact Polystyrene FINA TECHNOLOGY (US) 2018-02-01 US disclosed
US-9809699-B2 Alternative methods to control crosslinking in high impact polystyrene FINA TECHNOLOGY, INC. (US) 2017-11-07 US disclosed
US-20170121501-A1 ALTERNATIVE METHODS TO CONTROL CROSSLINKING IN HIGH IMPACT POLYSTYRENE FINA TECHNOLOGY, INC. 2017-05-04 US disclosed
EP-2964810-B1 ELECTROCHEMICAL METHOD FOR COUPLING PHENOL TO ANILINE EVONIK DEGUSSA GMBH (DE) 2016-11-23 EP disclosed
WO-2002100910-A1 MOLYBDENUM-BASED CATALYST COMPOSITION FOR PRODUCING SYNDIOTACTIC 1,2-POLYBUTADIENE BRIDGESTONE CORPORATION (JP) 2002-12-19 WO disclosed
WO-2002075420-A1 COLORED RADIATION CURABLE COATING COMPOSITIONS FOR IDENTIFYING TELECOMMUNICATIONS ELEMENTS AND TELECOMMUNICATIONS ELEMENTS COATED THEREBY ALCATEL (FR) 2002-09-26 WO disclosed
WO-1998058911-A2 PROSTAGLANDIN AGONISTS PFIZER INC. (US) 1998-12-30 WO disclosed
EP-0485472-A1 BIS-CYCLIC PHOSPHITE COMPOUNDS AND POLYMERIC MATERIALS STABILIZED THEREWITH EASTMAN KODAK COMPANY (US) 1992-05-20 EP disclosed
EP-0437493-A1 CYCLIC PHOSPHITES AND STABILIZED POLYMERIC COMPOSITIONS EASTMAN KODAK COMPANY (US) 1991-07-24 EP disclosed
WO-1991001987-A1 BIS-CYCLIC PHOSPHITE COMPOUNDS AND POLYMERIC MATERIALS STABILIZED THEREWITH EASTMAN KODAK COMPANY (US) 1991-02-21 WO disclosed
US-4956406-A Oxidation resistance of polypropylene or copolymers also heat resistance and radiation resistance EASTMAN KODAK COMPANY (US) 1990-09-11 US disclosed
US-4929654-A HEAT RESISTANCE, LIGHT RESISTANCE EASTMAN KODAK COMPANY (US) 1990-05-29 US disclosed
WO-1990003976-A1 CYCLIC PHOSPHITES AND STABILIZED POLYMERIC COMPOSITIONS EASTMAN KODAK COMPANY (US) 1990-04-19 WO disclosed
EP-0363270-A1 Cyclic phosphites and stabilized polymeric compositions EASTMAN KODAK COMPANY (US) 1990-04-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230098332-A1 HETEROCYCLIC DERIVATIVES AS TRMP8 ANTAGONISTS TRPM8, TRPM7, TRPM5 GABRA1 1927/4885GABRB2 1044/4885AMY1A 3990/4885
US-10960088-B2 Macrocycles, cobalt and iron complexes of same, and methods of making and using same ABCB7, FECH, CYC1 GABRA1 3802/4885GABRB2 3775/4885AMY1A 3991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.